Residency · Residency · Radiation Oncology
Reirradiation: Principles, Cumulative Toxicity, and Clinical Decision-Making
Introduction
Reirradiation involves delivering a second course of radiation therapy to an anatomical region that has previously received radiation. With improvements in cancer survival and the occurrence of local or regional recurrences within prior radiation fields, reirradiation is becoming more common in clinical practice. The primary challenge in reirradiation is to achieve therapeutic benefit while respecting the cumulative tolerance of normal tissues. This lecture explores the fundamental principles of reirradiation, the concept of tissue recovery, and the clinical scenarios where reirradiation is most frequently applied.
Radiobiologic Principles
Cumulative Dose and Tissue Memory
Normal tissues retain a partial memory of prior radiation exposure, which influences their response to subsequent radiation. Late-responding tissues such as the spinal cord, brain, and bowel have limited regenerative capacity, making them particularly vulnerable to cumulative injury. The extent of residual injury after initial radiation depends on factors including the initial dose delivered, the time interval since treatment, and the specific tissue type involved. Because complete tolerance recovery cannot be assumed, a conservative approach to reirradiation is standard practice.
Tissue Recovery Over Time
Tissue recovery after radiation varies by organ. Preclinical data suggest that the spinal cord recovers approximately 25-30% of its tolerance by six months post-radiation, with recovery potentially reaching up to 50% after two to three years; however, human data remain limited. The brain appears to follow a similar recovery pattern, though clinical evidence is scarce. The lung demonstrates some degree of recovery, but this is poorly characterized. The bowel shows limited recovery, and cumulative dose is a strong predictor of toxicity. Skin and subcutaneous tissues exhibit moderate recovery capacity.
BED and EQD2 Calculations
The biologically effective dose (BED) is a useful metric that allows comparison of different fractionation regimens by accounting for total dose and fraction size. When planning reirradiation, calculating the cumulative BED to organs at risk (OARs) is essential. The equivalent dose in 2 Gy fractions (EQD2) is the standard for dose comparison, facilitating assessment of cumulative exposure. Selecting the appropriate alpha/beta ratio is critical: a value of 3 Gy is used for late-responding tissues, while 10 Gy is applied for tumors and acute-responding tissues.
Clinical Scenarios for Reirradiation
Head and Neck Cancer
Locoregional recurrence after definitive chemoradiation in head and neck cancer occurs in 20-40% of cases. When surgery is not feasible, reirradiation offers a potential curative option. Trials such as RTOG 9610 and RTOG 0421 have investigated reirradiation combined with concurrent chemotherapy, reporting median survival times of 8 to 12 months and two-year overall survival rates of 15-25%. However, significant toxicity is a concern, with grade 5 treatment-related deaths occurring in 5-8% of patients. Typical reirradiation doses are around 60 Gy delivered in 30 to 40 fractions, either as 1.5-2 Gy twice daily or 1.8-2 Gy daily. Stereotactic body radiation therapy (SBRT) reirradiation, delivering 40-44 Gy in 5 fractions, is an emerging option that may offer a better therapeutic ratio.
Recurrent Rectal Cancer
Pelvic reirradiation is employed for recurrent rectal cancer after prior chemoradiation. Full-dose reirradiation, such as 30-39 Gy with concurrent chemotherapy, can facilitate R0 surgical resection. However, cumulative toxicity to the bowel and bladder limits the dose that can be safely delivered. Advanced techniques like intensity-modulated radiation therapy (IMRT) and proton therapy may reduce exposure to organs at risk in this setting.
Recurrent Lung Cancer/Thoracic Reirradiation
For lung cancer recurrence within a previously irradiated field, SBRT is often utilized. Careful assessment of the cumulative lung and esophageal doses is critical, with attention to prior mean lung dose and V20 values. Typical SBRT reirradiation regimens involve delivering 50 Gy in 5 fractions, provided that dose constraints can be met.
Spine SBRT Reirradiation
Spine SBRT reirradiation is addressed in detail in Lecture 68. The cumulative dose to the thecal sac is a critical consideration, with an assumption of approximately 25% recovery of spinal cord tolerance after more than six months.
Brain Reirradiation
Reirradiation of the brain is commonly performed using stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) for recurrent brain metastases or gliomas. The risk of radiation necrosis increases with cumulative dose. SRS retreatment is well-established for limited recurrence or progression.
Dose Constraints for Reirradiation
General Principles
When planning reirradiation, it is essential to calculate the cumulative EQD2 to all critical organs at risk by summing doses from prior and planned radiation courses. Conservative dose constraints should be applied, assuming only partial and incomplete tissue recovery. Individual patient factors such as diabetes, vascular disease, and connective tissue disorders can affect tissue tolerance and must be considered. Comprehensive documentation of all prior radiation details—including dose, fractionation, dates, treatment volumes, and techniques—is necessary to guide safe reirradiation.
Key Organ Cumulative Constraints (Approximate)
| Organ | Cumulative EQD2 Limit | Recovery Assumption | Key Consideration |
|---|---|---|---|
| Spinal cord | < 50–55 Gy | ~25% at 6 mo; up to 50% at 2–3 yr | Myelopathy irreversible; conservative approach essential |
| Brain | Volume-dependent; SRS point dose may exceed 60 Gy | Similar to cord (limited data) | Risk of necrosis increases with cumulative dose |
| Brachial plexus | < 65–70 Gy | Limited data | Plexopathy risk increases steeply above 66 Gy |
| Bowel | Complication risk increases > 60 Gy (D2cc) | Limited recovery | Fistula, perforation, obstruction |
| Esophagus | Dmax < 50–60 Gy | Limited data | Stenosis, fistula |
For the spinal cord, a cumulative EQD2 of less than 50-55 Gy is recommended, assuming an interval of more than six months and 25% recovery of tolerance. Brain dose constraints depend on the volume irradiated; point doses may exceed 60 Gy in the context of SRS. The brachial plexus should not exceed a cumulative EQD2 of 65-70 Gy. For the bowel, cumulative D2cc values vary, but complication rates increase above 60 Gy EQD2. The esophagus should be limited to a cumulative maximum dose (Dmax) of 50-60 Gy EQD2.
SBRT in the Reirradiation Setting
SBRT offers the advantage of steep dose gradients, which help protect previously irradiated tissues. This technique allows delivery of ablative doses to tumors while limiting exposure to organs at risk. SBRT is particularly useful for reirradiation of the spine, lung, and head and neck regions. Image guidance and motion management are critical components of SBRT to ensure precise targeting.
Treatment Planning Considerations
Imaging and Registration
Obtaining prior radiation treatment plans and dose distributions is crucial for accurate dose summation during reirradiation planning. Registration of the prior plan to the current planning CT is typically performed using deformable image registration (DIR). However, DIR has inherent uncertainties, especially for critical organs at risk, and should be used cautiously. When in doubt, worst-case scenario assumptions for critical structures should guide planning.
Deformable Image Registration Limitations
The accuracy of DIR decreases with significant anatomical changes such as surgery or tumor progression. In these cases, point-dose constraints may be more reliable than volumetric dose-volume histogram (DVH) summation. Clinical judgment must supplement quantitative dose summation to ensure patient safety. The American Association of Physicists in Medicine (AAPM) Task Group 132 provides guidelines for image registration in radiation therapy.
Technique Selection
Techniques such as IMRT and volumetric modulated arc therapy (VMAT) enable conformal dose sculpting around previously irradiated organs at risk. Proton therapy offers superior dose conformity and reduced integral dose, making it ideal for reirradiation. SBRT provides steep dose gradients that limit dose spread to surrounding tissues. Brachytherapy is an excellent option for localized recurrences, such as in head and neck or cervical cancers.
Complications of Reirradiation
Acute Toxicity
Acute toxicities during reirradiation are generally manageable and resemble those seen during the initial course of radiation. However, they may be exacerbated by residual late effects from prior treatment. Common acute toxicities include mucositis, dermatitis, and esophagitis, depending on the treatment site.
Late Toxicity
Late toxicities are more concerning and include irreversible myelopathy, which is the most feared complication of spinal or central nervous system reirradiation. Osteoradionecrosis, particularly of the mandible, is a notable risk in head and neck reirradiation. Fistula formation can occur in various locations such as tracheoesophageal, rectovaginal, or vesicovaginal sites. Hemorrhage, including carotid blowout syndrome, is a rare but often fatal complication in head and neck reirradiation. In pelvic reirradiation, bowel obstruction or perforation may develop. The rate of grade 5 toxicity in head and neck reirradiation series ranges from 3 to 8%.
Risk Mitigation
To mitigate risks, conservative dose constraints should be applied with assumptions of only partial tissue recovery. Advanced techniques such as SBRT and proton therapy help minimize exposure to organs at risk. Close surveillance during and after treatment is essential, and multidisciplinary evaluation should precede any decision to proceed with reirradiation.
Key Clinical Pearls
Reirradiation requires meticulous calculation of cumulative EQD2 to all critical organs at risk, with the assumption that tissue recovery is only partial. The spinal cord recovers approximately 25-30% of its tolerance by six months post-radiation, and this recovery factor should be applied conservatively in planning. Techniques such as SBRT and proton therapy provide dosimetric advantages by minimizing dose to previously irradiated normal tissues. Although head and neck reirradiation carries a significant risk of treatment-related mortality (5-8%), it may represent the only curative option for recurrent disease. It is imperative to obtain and thoroughly review prior radiation treatment records—including dose, fractionation, dates, and volumes—before making any reirradiation decisions.
References
- Nieder C, Grosu AL, Andratschke NH, et al. Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys. 2006;66(5):1446-1449.
- Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281-288.
- Verma V, Rwigema JCM, Malyapa RS, et al. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. Radiother Oncol. 2017;125(1):21-30.
- Sahgal A, Ma L, Weinberg V, et al. Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(1):107-116.